Clinical Trial

Zorifertinib With Osimertinib for NSCLC With Meningeal Progression

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This is a clinical trial that aims to test Zorifertinib when used together with a known drug, Osimertinib. The goal is to learn if this combination is safe and works for people with advanced Non-Small Cell Lung Cancer (NSCLC) whose cancer has spread to the membranes surrounding the brain and spinal cord (a condition called leptomeningeal metastases) after being treated with Osimertinib.
Protocol Amendment History 2 changes
critical Recruitment opened 2026-06-23
notable Trial sites expanded: 1 -> 5 locations 2026-06-23
Trial Details
NCT Number NCT07361705
Lead Sponsor Alpha Biopharma (Jiangsu) Co., Ltd.
Conditions Patients With Advanced Non-small Cell Lung Cancer With Meningeal Progression After Osimertinib Treatment
Enrollment 42 participants
Start Date 2026-01-31
Primary Completion 2028-04-23 (estimated)
Study Completion 2028-09-15 (estimated)
Updated on ClinicalTrials.gov 2026-06-22